Tremelimumab

Abstract

The IgG2 monoclonal antibody tremelimumab blocks the interaction between CTLA-4 and CD80/CD86. Recently, the substance was approved for two indications: in combination with durvalumab and platinum-based chemotherapy for the first-line therapy of metastatic non-small cell lung cancer without EGFR or ALK mutations, and in combination with durvalumab for the first-line therapy of adults with advanced or unresectable hepatocellular carcinoma. The data from the POSEIDON and HIMALAYA studies were the basis for approval.